跳至主要内容
临床试验/TCTR20220214005
TCTR20220214005Enrolling By Invitation1 期

Effects of colchicine on renal fibrosis marker in patients with chronic kidney disease: A randomized controlled trial

/A0 个研究点目标入组 40 人开始时间: 2022年2月14日最近更新:
适应症

试验速览

阶段
1 期
状态
Enrolling By Invitation
发起方
入组人数
40

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 Years 至 85 Years(—)
性别
All

入选标准

  • 1. Adult patients, age between 18 to 85 years old
  • 2. Chronic kidney disease stage 3 and 4, defined by KDIGO criteria which eGFR by creatinine-based Thai GFR equation is 15-59 ml per minute per 1.73 m2 of body surface area.

排除标准

  • 1) acute kidney injury within 1 month before randomization
  • 2) colchicine exposure within 3 month before randomization
  • 3) kidney transplant patients
  • 4) pre-existing or plan for immunosuppressive therapy
  • 5) woman with pregnancy, lactation or unwilling to take contraception methods
  • 6) cirrhosis or active hepatitis defined by elevated serum AST and/or ALT twice the upper limit
  • 7) chronic diarrhea
  • 8) neuromuscular disease
  • 9) hematologic disease or abnormal complete blood count, any of the following; hemoglobin < 10 g/dL, white blood count <3,000 x 109/L or Platelet <100,000 x 109/L
  • 10) active malignancy
  • 11) pre-existing use of strong CYP3A4 or P-glycoprotein inhibitors medication
  • 12) colchicine allergy
  • 13) active COVID-19 infection before 2 weeks before randomization.

研究者

发起方
/A

相似试验